SOPRANO is a phase II clinical trial for people with certain types of advanced ovarian cancer (including ovarian, fallopian tube and primary peritoneal cancer). The study is testing whether a highly targeted form of radiotherapy—stereotactic body radiotherapy (SBRT)—either on its own or followed by a drug called niraparib, can delay the need for further treatment such as chemotherapy.

Some patients in the trial have cancer that has grown or spread to only a small number of places in the body (1–3). This is known as oligoprogression or oligometastatic disease.

Participants are randomly placed into one of two groups:

• Group 1: SBRT followed by niraparib
• Group 2: SBRT alone

Each group will include 21 patients.

SBRT
SBRT delivers very precise, high‑dose radiotherapy directly to cancer cells while reducing exposure to healthy tissue.

Niraparib
Niraparib is a targeted cancer drug called a PARP inhibitor. It stops cancer cells from repairing themselves, which helps kill them. In this trial, researchers want to see if adding niraparib after SBRT helps the benefits of radiotherapy last longer.

• All participants receive 3–8 SBRT treatments over 5–19 days.
• Those in Group 1 take daily niraparib until their cancer worsens.
• Everyone attends follow‑up appointments with scans and check‑ups every 8 weeks in year one, then every 12 weeks in year two, and then as needed.
• If a participant’s cancer later worsens in only 1–3 places again, more SBRT may be considered. 
  Purpose of the Trial

The aim is to find out whether SBRT, with or without niraparib, can keep the cancer from progressing for at least 6 months after starting treatment. If the results are promising, larger studies may follow. The findings will be shared with participants and published to support future research.